Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/154,287external-prioritypatent/US20020012694A1/en
Application filed by Population Council IncfiledCriticalPopulation Council Inc
Publication of AR017760A1publicationCriticalpatent/AR017760A1/en
Una forma de dosificacion transdérmica que comprende una cantidad terapéuticamente efectiva de un androgeno no reducible en 5-alfa dispersa en un vehículotransdérmico aceptable farmacéuticamente aceptable. La forma de dosificacion transdérmica puedeser un unguento, una crema, un gel, un polvo, un parchetransdérmico, una locion, una solucion atomizadora o similares. El androgeno no reducible en 5-alfa preferido es un androgeno 7 alfa modificado y en particular7-alfa-metil-19-nortestosterona (MENT). Preferiblemente, la forma de dosificacion transdérmica incluye una cantidad entre 0,5 y 10 mg aproximadamente de MENTdispersa en el vehículo transdérmico farmacéuticamente aceptable.A transdermal dosage form comprising a therapeutically effective amount of a non-reducible 5-alpha androgen dispersed in a pharmaceutically acceptable acceptable transdermal carrier. The transdermal dosage form can be an ointment, a cream, a gel, a powder, a transdermal patch, a lotion, an atomizing solution or the like. The preferred non-reducible 5-alpha androgen is a modified 7-alpha androgen 7 and in particular 7-alpha-methyl-19-nortestosterone (MENT). Preferably, the transdermal dosage form includes an amount between about 0.5 and 10 mg of MENT dispersed in the pharmaceutically acceptable transdermal vehicle.
ARP9801047361998-09-161998-09-22
A TRANSDERMAL DOSAGE FORM THAT INCLUDES A NON-REDUCING ANDROGEN IN 5-ALFA
AR017760A1
(en)
A topical formulation which induces a minimal systemic effect when applied to the skin, the topical formulation comprising an immunosuppressive macrolide selected from sirolimus, FK506 and SDZ ASM 981 and a permeation modulator for the treatment of a dermatological condition